HALO

In the past six months, Halozyme's stock has experienced several notable events. The company reported its Q4 2025 earnings on February 17, 2026, where it posted a loss of -$0.35 earnings per share (EPS), significantly missing the consensus estimate of $2.07 profit. In December 2025, Halozyme completed the acquisition of Surf Bio, Inc., expanding its drug delivery technology portfolio. Also in December 2025, a German court granted Halozyme's request for a preliminary injunction against Merck Sharp & Dohme Corp. In March 2026, Halozyme appointed David Ramsay as Interim Chief Financial Officer. Analysts have provided varied price targets and ratings for HALO stock during this period. The stock's 52-week range has been between $47.50 and $82.22.